Drug recall · September 21, 2016
buPROPion Hydrochloride Extended-Release Tablets recall
Why: Failed dissolution specifications - the out of specification result for dissolution was identified during 3 month stability testing.
Class III: unlikely to cause harm, but breaks the rules (for example a labeling error).
The recall
- Product
buPROPion Hydrochloride Extended-Release Tablets, USP (XL), 300mg, 500-count bottle, Rx only, Manufactured by: Cadila Healthcare Ltd., Ahmedabad, India For BluePoint Laboratories, NDC 68001-264-03
- Lots / codes
Lot #: MS1509, Exp 12/17
- Quantity
- 2626 bottles
- Company
- Amerisource Health Services, Columbus, OH
- Distribution
- Nationwide and Puerto Rico
- Initiated
- August 4, 2016 · Voluntary: Firm initiated
- Classified
- September 15, 2016
- Reported
- September 21, 2016
- Ended
- July 17, 2017
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Bupropion
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.